You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Sequencing-based newborn screening could not identify all children with metabolic disorders or hearing loss, but could interrogate a larger number of conditions.
In PNAS this week: Zika virus mutation linked to increased transmission, variants associated with inherited hearing loss, and more.
A study of families from the Netherlands revealed a RIPOR2 deletion as a common cause for hearing loss, making it a unique target for gene therapy.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
The researchers conducted genome-wide association studies of individuals who reported hearing difficulties and those who used hearing aids.
The test is the cornerstone of a study involving roughly a thousand patients from two British neonatal centers that is set to commence this fall.
Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.
In PNAS this week: sequencing analysis of Brooklyn measles cases, conserved neural transcriptional features that coincide with monogamy, and more.
The molecular test detects a form of herpes virus that can infect newborns and cause deafness.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.